PI: Rajiv Jalan (University College, London, UK)
Funder/Promoter: European Comission H2020 program
This is a European multi-centre, two phase project on the role of a new artificial liver support system (DIALIVE) in patients with ACLF. The first phase consists in a randomized controlled study, to evaluate the safety and performance of The DIALIVE Liver Dialysis Device in patients with ACLF versus standard of care. This trial is currently ongoing.
After successful completion of the DIALIVE Safety & Performance study, a second phase is planned, consisting of a randomized controlled trial of 100 patients, to assess the efficacy of the DIALIVE versus standard medical therapy in ACLF patients. The main aim-point is 3-month survival.